Real-World Efficacy of Faricimab in Treating Diabetic Macular Edema

Strategic Insights -

A study published in the Journal of Personalized Medicine has shed new light on the effectiveness of faricimab in treating diabetic macular edema (DME). The research, led by investigators at Odense University Hospital, found that faricimab improved best-corrected visual acuity and macular thickness in patients with DME, with treatment intervals extended by up to 81% in treatment-naive eyes and 78% in previously treated eyes. This breakthrough treatment has significant implications for patients with DME, a prevalent exudative maculopathy that can lead to severe vision loss.

Key Takeaways:

  • Faricimab, a novel anti-vascular endothelial growth factor (anti-VEGF) and anti-angiopoietin-2 bispecific agent, has been approved for the treatment of DME.
  • The systematic review of real-world evidence found that faricimab improved best-corrected visual acuity and macular thickness in patients with DME.
  • The extension of treatment intervals was possible in 61-81% of treatment-naive eyes and 36-78% of previously treated eyes.
  • The study yielded clinical outcomes similar to those known from previous anti-VEGF treatments but with extended treatment intervals.
  • Long-term real-world studies are warranted to further investigate the efficacy of faricimab in treating DME.

Statistics:

  • 6054 eyes with DME were included in the study, with a mean follow-up of between 55 days and 12 months.
  • 10 eligible studies were reviewed, five of which reported outcomes in a population of both treatment-naive and previously treated eyes, and five of which reported outcomes exclusively in relation to eyes that were previously treated.
  • The extension of treatment intervals was possible in 61-81% and 36-78% of treatment-naive and previously treated eyes, respectively.

Sources:

  • Real-World Efficacy of Intravitreal Faricimab for Diabetic Macular Edema: A Systematic Review. Journal of Personalized Medicine, 2024, 14(9).
  • Journal of Personalized Medicine - http://www.mdpi.com/journal/jpm
  • MDPI AG - publisher for Journal of Personalized Medicine.